The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat
The effect of candesartan, an angiotensin-II type-1 receptor antagonist, on the metabolic profile and renal inflammation is unclear. We evaluated this relationship by feeding male lean (LZ) and obese (OZ) Zucker rats chow or chow with candesartan (23.5 mg/kg⋅diet) for 14 weeks (n=6–8/treatment/body...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2010/841343 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563944492892160 |
|---|---|
| author | Carolyn M. Ecelbarger Arjun Rash Rajesh K. Sinha Swasti Tiwari |
| author_facet | Carolyn M. Ecelbarger Arjun Rash Rajesh K. Sinha Swasti Tiwari |
| author_sort | Carolyn M. Ecelbarger |
| collection | DOAJ |
| description | The effect of candesartan, an angiotensin-II type-1 receptor antagonist, on the metabolic profile and renal inflammation is unclear. We evaluated this relationship by feeding male lean (LZ) and obese (OZ) Zucker rats chow or chow with candesartan (23.5 mg/kg⋅diet) for 14 weeks (n=6–8/treatment/body type). Candesartan reduced serum triglycerides, plasma creatinine, urine albumin, and renal cortical collagen and glycogen deposition in the OZ. An ELISA-based cytokine array revealed that candesartan normalized elevated renal interleukin (IL) 1-β and monocyte chemoattractant protein-1 (MCP-1) levels in OZ. Nonetheless, candesartan impaired glucose tolerance, and did not lower blood insulin or glucose levels. Moreover, renal IL-1α, -2, -4, -6 and -10 tumor necrosis factor-α, interferon-γ, were
significantly reduced in OZ relative to LZ, and increased by candesartan. Furthermore, candesartan increased growth-regulated oncogene, transforming growth factor-β1 and IL-18
in OZ kidneys to a level higher than LZ or untreated OZ. Candesartan did not affect renal cytokine levels in LZ. Overall, candesartan attenuated renal disease and improved renal function in OZ, despite mixed effects on metabolic factors and cytokines. Reduced plasma
triglycerides and/or renal MCP-1 and IL-1β may have had a role in this protection. However,
these effects were clearly independent of any improvement in glucose tolerance. |
| format | Article |
| id | doaj-art-db38fe7080e54da7a62d9c210613f0a4 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-db38fe7080e54da7a62d9c210613f0a42025-02-03T01:12:13ZengWileyMediators of Inflammation0962-93511466-18612010-01-01201010.1155/2010/841343841343The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker RatCarolyn M. Ecelbarger0Arjun Rash1Rajesh K. Sinha2Swasti Tiwari3Division of Endocrinology and Metabolism, Department of Medicine, Georgetown University, Washington, DC 20057, USADivision of Endocrinology and Metabolism, Department of Medicine, Georgetown University, Washington, DC 20057, USALaboratory of Immunoregulation, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USADivision of Endocrinology and Metabolism, Department of Medicine, Georgetown University, Washington, DC 20057, USAThe effect of candesartan, an angiotensin-II type-1 receptor antagonist, on the metabolic profile and renal inflammation is unclear. We evaluated this relationship by feeding male lean (LZ) and obese (OZ) Zucker rats chow or chow with candesartan (23.5 mg/kg⋅diet) for 14 weeks (n=6–8/treatment/body type). Candesartan reduced serum triglycerides, plasma creatinine, urine albumin, and renal cortical collagen and glycogen deposition in the OZ. An ELISA-based cytokine array revealed that candesartan normalized elevated renal interleukin (IL) 1-β and monocyte chemoattractant protein-1 (MCP-1) levels in OZ. Nonetheless, candesartan impaired glucose tolerance, and did not lower blood insulin or glucose levels. Moreover, renal IL-1α, -2, -4, -6 and -10 tumor necrosis factor-α, interferon-γ, were significantly reduced in OZ relative to LZ, and increased by candesartan. Furthermore, candesartan increased growth-regulated oncogene, transforming growth factor-β1 and IL-18 in OZ kidneys to a level higher than LZ or untreated OZ. Candesartan did not affect renal cytokine levels in LZ. Overall, candesartan attenuated renal disease and improved renal function in OZ, despite mixed effects on metabolic factors and cytokines. Reduced plasma triglycerides and/or renal MCP-1 and IL-1β may have had a role in this protection. However, these effects were clearly independent of any improvement in glucose tolerance.http://dx.doi.org/10.1155/2010/841343 |
| spellingShingle | Carolyn M. Ecelbarger Arjun Rash Rajesh K. Sinha Swasti Tiwari The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat Mediators of Inflammation |
| title | The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat |
| title_full | The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat |
| title_fullStr | The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat |
| title_full_unstemmed | The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat |
| title_short | The Effect of Chronic Candesartan Therapy on the Metabolic Profile and Renal Tissue Cytokine Levels in the Obese Zucker Rat |
| title_sort | effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese zucker rat |
| url | http://dx.doi.org/10.1155/2010/841343 |
| work_keys_str_mv | AT carolynmecelbarger theeffectofchroniccandesartantherapyonthemetabolicprofileandrenaltissuecytokinelevelsintheobesezuckerrat AT arjunrash theeffectofchroniccandesartantherapyonthemetabolicprofileandrenaltissuecytokinelevelsintheobesezuckerrat AT rajeshksinha theeffectofchroniccandesartantherapyonthemetabolicprofileandrenaltissuecytokinelevelsintheobesezuckerrat AT swastitiwari theeffectofchroniccandesartantherapyonthemetabolicprofileandrenaltissuecytokinelevelsintheobesezuckerrat AT carolynmecelbarger effectofchroniccandesartantherapyonthemetabolicprofileandrenaltissuecytokinelevelsintheobesezuckerrat AT arjunrash effectofchroniccandesartantherapyonthemetabolicprofileandrenaltissuecytokinelevelsintheobesezuckerrat AT rajeshksinha effectofchroniccandesartantherapyonthemetabolicprofileandrenaltissuecytokinelevelsintheobesezuckerrat AT swastitiwari effectofchroniccandesartantherapyonthemetabolicprofileandrenaltissuecytokinelevelsintheobesezuckerrat |